{"disease":{"id":"unresectable-malignant-melanoma-with-braf-gene-mutation","name":"Unresectable malignant melanoma with BRAF gene mutation","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"encorafenib","indication_name":"Unresectable malignant melanoma with BRAF gene mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Braftovi","generic_name":"encorafenib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"RAF proto-oncogene serine/threonine-protein kinase","drug_class":"","quality_score":83,"revenue":"716","mechanism":"Braftovi works by blocking the activity of a specific protein called BRAF that is involved in cancer cell growth."},{"drug_id":"binimetinib","indication_name":"Unresectable malignant melanoma with BRAF gene mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mektovi","generic_name":"binimetinib","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Mektovi works by blocking a specific enzyme called MEK1, which is involved in sending signals that promote cancer cell growth."},{"drug_id":"mek162","indication_name":"Unresectable malignant melanoma with BRAF gene mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mektovi","generic_name":"mek162","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 1","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Mektovi works by blocking the MEK1 enzyme, which is a key player in the signaling pathway that promotes cancer cell growth."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}